Practical Implications of Recent Changes to
Immunogenicity Risk Assessment
Speaker Bio
Jing Shi, PhD
Global Head of Large Molecule Bioanalysis
Dr. Shi leads the bioanalytical method development, validation and sample testing services under GLP/GCP, in support of our clients.
She has extensive working experience at various drug development stages including cell line development, process development, toxicology, biologics drug substance/drug product characterization and preclinical/clinical bioanalytical analysis